New Framework Uncovers 21 Existing Drugs with Pro-Longevity Potential

A new gene network-based framework predicts the potential of existing drugs to confer pro-longevity effects.

A new gene network-based framework predicts already-approved repurposable drugs that may either confer pro-longevity benefits or age-accelerating effects.

Aging &amp; Longevity

Model: 699 European adults with an average age of 63.11 years

Longest Aging Clock Study to Date Shows Robust Improvement in Mortality Risk Prediction

A new study provides evidence that using aging clocks based on molecular tagging patterns on DNA (epigenetic aging clocks) to take multiple age readings across time outperforms taking single measurements in predicting mortality.

(The study’s principal investigator, Luigi Ferrucci | LinkedIn)

An Institute for Research on Aging study provides evidence that using epigenetic aging tests at multiple time points predicts mortality better than a single measurement.

Epigenetics

Model: Old male mice
Dosage: 100 mg/kg/day of ALA administered in drinking water

Restoring the naturally occurring antioxidant, alpha-lipoic acid (ALA), to the gut wall rejuvenates stem cells and counters age-related gut degeneration in mice and human models. 

Images of miniature intestines developed from intestinal stem cells. 

Top Evidence-Based Interventions to Lower Biological Age

Epigenetic aging clocks estimate biological age based on DNA molecular tagging patterns, and interventions like semaglutide and ketamine reduce these estimates in humans.

(The principal investigator behind the review on interventions that influence biological age, Dr. David Sinclair | The Society of the Four Arts)

As reviewed in this article, epigenetic aging clocks have estimated the effects of pharmaceutical interventions, lifestyle habits, supplements, and clinical interventions on biological age.

Model: C57BL/6 mice
Dosage: 500 mg/kg/day of SRN-901 via oral gavage for six days per week starting at 18 months of age; 14.4 ppm of rapamycin mixed in food starting at 18 months of age; 300 mg/kg/day of NMN via oral gavage for six days per week starting at 18 months of age; and 300 mg/kg/day of NR via oral gavage for six days per week starting at 18 months of age

Seragon Publishes Record-Breaking SRN-901 Longevity Data, Demonstrating 33% Lifespan Extension in Mice

In a newly published mouse study, SRN-901 extended remaining lifespan by 33%, slowed frailty progression, and lowered tumor incidence.

Seragon’s SRN-901 extended the remaining lifespan of adult mice by 33%, attenuated frailty progression by 70%, and reduced tumor incidence by 30.53%, according to a newly published preclinical study.

Search Result: SRN-901

New Framework Uncovers 21 Existing Drugs with Pro-Longevity Potential

Longest Aging Clock Study to Date Shows Robust Improvement in Mortality Risk Prediction

Alpha-Lipoic Acid Rejuvenates Stem Cells & Improves Gut, New Study Shows

Top Evidence-Based Interventions to Lower Biological Age

Seragon Publishes Record-Breaking SRN-901 Longevity Data, Demonstrating 33% Lifespan Extension in Mice